Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
| Autor: | Angelo Raffaele Bianco, J. Carpenter, Rory Collins, M. Abeloff, H. Mouridsen, O. Abe, Gianni Bonadonna, J. Crowley, Aman U. Buzdar, R. Cooper, Rowan T. Chlebowski, F. Boccardo, Jack Cuzick, Michael Baum, D. Ahmann, I. C. Henderson, Marc Buyse, K. Andersen, P. Carbone |
|---|---|
| Přispěvatelé: | Henderson, I, Mouridsen, H, Abe, O, Abeloff, M, Ahmann, D, Andersen, K, Baum, M, Bianco, A, Boccardo, F, Bonadonna, G, Buyse, M, Buzdar, A, Carbone, P, Carpenter, J, Chlebowski, R, Collins, R, Cooper, R, Crowley, J, Cuzick, J |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Adjuvant tamoxifen business.industry medicine.medical_treatment Combination chemotherapy General Medicine law.invention Collaborative group Randomized controlled trial law Internal medicine medicine business Cytotoxic Therapy Tamoxifen Early breast cancer medicine.drug |
| Popis: | We sought information worldwide on mortality according to assigned treatment in all randomized trials that began before 1985 of adjuvant tamoxifen or cytotoxic therapy for early breast cancer (with or without regional lymph-node involvement). Coverage was reasonably complete for most countries. In 28 trials of tamoxifen nearly 4000 of 16,513 women had died, and in 40 chemotherapy trials slightly more than 4000 of 13,442 women had died. The 8106 deaths were approximately evenly distributed over years 1, 2, 3, 4, and 5+ of follow-up, with little useful information beyond year 5. Systematic overviews of the results of these trials demonstrated reductions in mortality due to treatment that were significant when tamoxifen was compared with no tamoxifen (P Because it involved several thousand women, this overview was able to demonstrate particularly clearly that both tamoxifen and cytotoxic therapy can reduce five-year mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|